Articles published by HAYA Therapeutics

HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis

May 20, 2026

From HAYA Therapeutics

Via Business Wire

HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics Platform

June 03, 2025

From HAYA Therapeutics

Via Business Wire

HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer

March 13, 2025

From HAYA Therapeutics

Via Business Wire

HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer

September 11, 2024

From HAYA Therapeutics

Via Business Wire

HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award

July 01, 2024

From HAYA Therapeutics

Via Business Wire

HAYA Therapeutics Appoints Brian C. Thomas, Ph.D., as Chairperson of the Board of Directors

September 15, 2022

From HAYA Therapeutics

Via Business Wire

HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies

May 03, 2022

From HAYA Therapeutics

Via Business Wire

HAYA Therapeutics Establishes U.S. Location

February 09, 2022

From HAYA Therapeutics

Via Business Wire

HAYA Therapeutics Announces Scientific Advisory Board

August 10, 2021

From HAYA Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.